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The Importance of Early Detection for Alzheimer’s Disease
Mariah McKenzie
Eastern Kentucky University
Abstract: The number of Americans who are suffering from late diagnoses of Alzheimer’s disease
(AD) increases in the U.S. each year. Therefore, there is a need for more access toward early
detection of this disease in order to ensure optimal quality of life and treatments for individuals. AD
is one of the leading causes of deaths and, with the lack of funds for research, the number of AD
diagnoses is expected to continue to increase. Medicare, Medicaid, and National Institute of Health
services are providing funds for the current issues, however, it is not enough. There are many forms
of poor access to services for individuals to seek early detection, but if that can change and financial
assistance is provided, not only would many more individuals and their families benefit, but the
states and nation would as well.
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Alzheimer’s disease is a terminal illness that affects an
individual’s cognition. Although the disease is a condition that
is typically recognized in late adulthood, signs of memory loss
can occur as early as in the third decade of life (Ahmed, Baker,
& Butler, 2016). Currently, AD is the sixth leading cause of
death in the United States and every 65 seconds someone
develops the disease (Medletter Associates, 2015). With such a
high prevalence of AD, our nation is greatly impacted, and
changes need to be made. Care for AD is extremely expensive,
and without an increase in funding for research, there may never
be a cure.
National and State Healthcare Issue
Of all diseases affecting Americans, AD is the most
expensive, totaling to roughly 277 billion dollars in 2018
(Alzheimer’s Association, 2019). Among those billions of
dollars, about 186 billion came from Medicare and Medicaid
(“Alzheimer's Disease Facts and Figures,” 2018). These state
and nationally funded programs are spending the most amount
of the American tax dollars on this disease, yet, even with
society’s contribution to the taxes, there is hardly any progress
in AD research for a prevention or cure, as the money is
predominately used for maintenance of care for those already
diagnosed (Alzheimer’s Association, 2019). If AD diagnoses
could be made earlier, less of the Medicare and Medicaid
dollars would be spent on treating this diagnosis. Indeed, if this
were the case, the individuals would be receiving assistance
sooner and, as a result, would be able to plan out their desired
course of treatment throughout a longer span than an individual
who is diagnosed later and needs serious and constant medical
attention (Alzheimer’s Association, 2019). Perhaps most
importantly, this change could allocate a larger portion of the
Medicare and Medicaid’s assistance toward finding a
prevention or cure. “Among all Americans alive today, if those
who will get Alzheimer's disease were diagnosed when they had
mild cognitive impairment, before dementia, it would
collectively save $7 trillion to $7.9 trillion in health and longterm care costs” (Alzheimer's Disease Facts and Figures, 2018,
p. 57).
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In addition to this being a huge shift in research, this would
also mean that another large portion of the money could be
spent on imaging and neurological examinations which are
greatly needed to diagnose individuals. Indeed, although these
tests are costly, they are essential to officially determine if the
individual truly has AD. In addition, if the individual has the
access for these images and exams early, it will save them
money overall. From a national healthcare perspective, there is
also less of an expense for AD discovered while the individual
is in the mild cognitive impairment stage, compared to
diagnosing the disease while the individual has progressed to
the dementia stage (Alzheimer’s Association, 2019). This is due
to the rapid spikes in costs directly before and after late
diagnosis (Alzheimer’s Association, 2019). Indeed, because
individuals diagnosed with AD in the mild cognitive
impairment stage have had time to plan their medical future and
are aware of the cause of their illness, by the time they have
reached the dementia stage, they have significantly less longterm care and medical costs. Furthermore, by the time of
reaching dementia, these individuals have their mild cognitive
impairments controlled and managed (Alzheimer’s
Association, 2019). Unfortunately, those diagnosed late also
have unmanaged mild cognitive impairment, which likely
resulted in many doctors’ visits and unnecessary costs toward
symptom control, and could have been managed by a
neurological examination to pinpoint the illness and begin
treatment (Alzheimer’s Association, 2019). Then, all at once,
the individual diagnosed late may need the medical imaging and
many other tests in a short period of time, in addition to other
long-term and constant care, which are large expenses
(Alzheimer’s Association, 2019).
Impacts on Delivery of Healthcare
Access to early detection of AD allows individuals to have
options for various forms of testing. Most recently, research has
shown that the use of biomarkers in relation to cerebral spinal
fluid has been found to show the earliest indications of the
development of mild cognitive impairment (Buracchio & Kaye,
2009). Unfortunately, these tests and procedures are extremely
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costly. Indeed, this can become a financial burden to the
individual and the family, if even affordable. Currently,
Medicare covers tests such as blood studies, urinalysis,
electrocardiograms, chest X-rays, computerized tomography
(CT) scans, electroencephalography (EEG), and magnetic
resonance imaging (MRI) to assist in the diagnostic process.
Positron emission tomography (PET) scans have been shown to
be one of the better tools to assist in diagnosis, as they examine
the deposits of amyloid protein plaque in the brain, which can
occur years before any clinical signs of AD (Marcus, Mena, &
Subramaniam, 2014). Furthermore, these scans can even show
differentiation to target the specific type of dementia, including
AD (Marcus, Mena, & Subramaniam, 2014). However, when
used for diagnosing AD, they are very rarely covered by
Medicare (Alzheimer’s Association, 2019). Without the
financial assistance of Medicare, individuals likely suffer a lack
of access to this very important test. Indeed, PET scans play an
integral role in the diagnostic process, and should be covered
by Medicare, especially for individuals with AD. With the
prevalence of the disease increasing, it is vital to locate and
share information about early detection. If caught early, many
cases could begin receiving treatments and develop a plan of
action before the disease takes the majority of the person’s
cognition (Marcus, Mena, & Subramaniam, 2014).
Population Impacted
Many individuals, families, and workers are affected by
Alzheimer’s disease. Indeed, as of 2018, 5.5 million Americans
over the age of 65 have a diagnosis of AD, and, with the baby
boomer generation aging, this statistic is expected to
dramatically increase for the next several decades
(“Alzheimer's Disease Facts and Figures,” 2018). This illness is
not a small matter. It affects millions of individuals in this
country and will continue to develop and impact more if
significant changes are not made.
When considering AD and the population that it affects, it
is common to focus on the individual, however, the family and
caregivers also play roles into the individual’s access for care.
Family, close friends, and other unpaid workers make up 83
percent of aid for the late adulthood population. Nearly half of
all care giving are for individuals suffering from AD or
dementia (Alzheimer’s Association, 2019). These caregivers
are working with the AD population in what means may be
available. This can result in family members assuming that role
of primary care giver, but they may lack in healthcare
knowledge which ultimately affects the individual’s care
(Taylor, Bouldin, & McGuire, 2018). The caregivers may not
know of the available resources, may know the person cannot
financially afford testing, or may struggle accepting the harsh
reality that a person they love has mild cognitive impairments
and could benefit from early detection (Bynum, 2014). Another
consideration is the cost to the individual. Even if their care is
coming primarily from unpaid family members, the financial
burden on the individual including the costs for comorbidities
add to an estimated $28,500 per individual per year (Fishman,
2013). Those costs greatly impact the individual for the access
of care that they can afford. In addition, if the individual has a
family, these yearly financial obligations to manage the
individual’s care could greatly impact the way the whole family
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functions. It could limit the family’s ability to engage in valued
occupations due to financial means.
Thesis statement
More Americans are suffering from late diagnoses of
Alzheimer’s disease in the U.S. each year. Therefore, there is a
need for more access toward early detection of this disease in
order to ensure optimal quality of life and financially affordable
care.
Relationship
Connection to Course Content
When evaluating why individuals may not be tested for AD
when exhibiting signs of mild cognitive impairment, it is
important to consider the availability of care. According to Shi
and Singh (2019), there are dimensions of access that can affect
an individual’s ability to receive care: availability, accessibility,
and accommodation. In regards to availability, the family plays
a critical role. Indeed, if the family does not recognize the need
for early AD testing, the individual suffers without ever gaining
the opportunity to be seen by a doctor for early diagnostic
services. Additionally, another condition may be due to the
negative stigmas associated with AD. The family of those
individuals may have a resistant mindset regarding seeking help
and, therefore, may be hesitant to employ a neurological
examination. Lastly, another availability consideration is
financial piece. With current funds, the cost for AD services and
examinations may be outside of the financial scope. Lastly, AD
individuals may experience a lack of access to care because they
simply are not receiving enough assistance to be able to be seen
by a doctor.
Another dimension is described as accessibility (Shi &
Singh, 2019). Accessibility becomes a concern when
individuals do not have access to a transportation in order to
travel to a location where there is a knowledgeable AD
provider. This issue can occur if the individuals do not have
their own vehicle or do not have the ability to drive themselves
the distance to the healthcare provider. For example,
individuals in late adulthood are often limited to driving short
distances that are 15 minutes or less, however, it is not
uncommon to find that the closest medical provider is 45
minutes away. Individuals in such a predicament are restricted
to care that could take place in their home or reliance on another
person to drive them to an appointment. In this dimension of
care, the transportation limitations are what is keeping the
individual from quality care (Shi & Singh, 2019).
In regards to accommodation, scheduling is often the
primary issue. Indeed, when an individual has concerns
regarding their mental functioning, the individual’s primary
care physician sends a referral to a specialist, however, the
specialized practitioner may not have a work schedule that
aligns the individual’s needs (Shi & Singh, 2019). Additionally,
a second conflict may be the individual’s work schedule. If the
individual is still working, they may need a very early
appointment before work, yet the specialist may not come in the
office until noon. This would delay the individual’s ability to
be seen by the specialist until there is a match of the two
schedules, if ever seen at all. Indeed, this may restrict the
individual from being seen for long periods of time, which
would delay the individual on a very time sensitive matter (Shi
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& Singh, 2019). If the individual is not seen due to time
conflicts, they could be progressing through early stages of AD
without even knowing it. By the time it is discovered by the
specialist, the individual may be in a later stage than they would
have if an appointment could have been made fitting their
schedule.
Application to Occupational Science
Access for early detection of AD can be limited due to
various types of occupational injustices. Someone that
experiences occupational deprivation could struggle going to
the doctor because they may notice a change in their behaviors
and feel like the memory loss is out of their control (Hasselkus,
2011). The individual could feel like a piece of their personal
identity is being taken away by this disease, and seclude
themself from anything that used to be enjoyable (Kielhofner,
2008). In addition, this may lead to avoid engaging in
occupations in which another person might refer them to a
doctor due to the drastic changes in ability to occupationally
perform. What level the individual could previously perform at
may be substantially different than their current abilities, which
may be noticeable enough to warrant attention.
On the other hand, individuals may feel their memory
lapses are temporary, so they refrain from participating in their
occupations during these particular times of the day and also
may feel that their memory lapses are not severe enough to see
a practitioner about the potential condition (Hasselkus, 2011).
According to Black (2018), symptoms of anxiety may emerge
when discussing a potential diagnosis of AD to an individual.
Indeed, this may cause worry and questioning, and lead the
individual to solitary engagements to avoid any additional
anxiety. Furthermore, there could be a transition to a denial
period in which the individual does not believe or truly see the
reality of their health status (Hasselkus, 2011). This form of
injustice, called disruption, restricts individual’s access to their
healthcare needs because they limit their own ability and view
to see the issue themselves (Hasselkus, 2011).
Another area to consider is access to medical professionals
who have a valued sense of client-centered care. In this case,
the provider is aware and knowledgeable of the client’s
concerns and behaviors, and provides services that are focused
on ensuring the best support for that client’s life (Hasselkus,
2011). By practicing client-centered care, the practitioner can
promote ideas regarding ways to implement the client’s
interests within the realms of ability due to AD. For example,
to encourage a single, male client who enjoys cooking with his
friends, a provider may recommend that he begin going to
restaurants with his friends instead. Indeed, this would still
allow the client to participate in a social activity with his
friends, but without risking injuring himself in the kitchen while
cooking. This example is also especially helpful for clientcentered care, not only because it allows the client to engage in
their interests, but because it is also medically beneficial.
Engaging in social activities is especially important for
individuals with AD to promote cognitive functioning and,
typically, women participate in this more than men (Mielke,
2018). By providing quality care, the practitioner is able to
understand clients in a more holistic manner and truly make a
bigger difference.
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Relevance
Current Healthcare Policies
When viewing current healthcare policies, it is important
to examine the funding and logistics of the available programs
and services. “In 2011, Congress passed the National
Alzheimer’s Project which mandated a National Plan to
Address Alzheimer’s Disease in 2012, that set a target date of
2025 to develop methods of prevention and effective treatment”
(Black, 2018). The National Institute of Health (NIH)
redirected 40 million dollars in the budget to AD research in the
year 2013 and has continued to be a financial support (Black,
2018). Since then, access to healthcare has become more
affordable and available.
Drug rebates is an apt example of the increase in access.
Before funding increases, Medicare had a cap on prescriptions
and if a patient hit that cap, they would have to pay the rest of
the amount out of pocket. By 2020, this will be phased out as
Medicare will cover the full expense (Jiang, Hughes, & Wang,
2018). Another policy that has been enacted is the use of annual
wellness visits, which are also funded by Medicare. Although
these have already been in place, they now include cognitive
impairment screens to assess for symptoms of AD or dementia,
as well as talk with the family, caretakers, friends about any
possible concerns. With this legislature in place, there has been
an improved delivery on preventative care (Jiang, Hughes, &
Wang, 2018).
Unfortunately, the NIH’s contribution to AD is scarce in
relation to its need. In comparison to funding for other leading
diseases in the U.S., AD funding is significantly less. Indeed,
the NIH provides over 6 billion dollars yearly for cancer, which
is 150 times the amount spent on AD. For yearly funding for
heart disease, over 4 billion dollars is spent, or 100 times the
funding given to AD. Lastly, the NIH assistance in HIV/AIDS
support is over 75 times the amount of AD, adding to the 3
billion dollars yearly (Black, 2018). Although funding for AD
is increasing, much more support is needed to make true strides
in research for such a prevalent disease.
Implications of Early Detection
There are many steps that need to be taken for
improvement of access toward early detection of AD. First and
foremost, additional funding is crucial for any major progress.
According to Black (2018), with the limited federal financial
support, the U.S. is far from finding a cure or even the
prevention of AD. An avenue that could be taken to increase the
funding could be advocating for the NIH to reallocate more
funds for AD research. When evaluating the leading causes of
death, HIV/AIDS is ranked below AD, yet receives seventyfive times the funding (Black, 2018). If some funds could be
reallocated from HIV/AIDS to make a more proportional
distribution relating to ranking of leading causes of death, there
could be major improvements and advancements in the AD
field.
When considering the individual, going to the doctor and
having services recommended to be tested for AD in the early
stages of cognitive decline can result in faster medication
prescriptions, faster access to a medical specialist concerning
care, and faster plan of action for the family (Alzheimer’s
Association. 2019). Early detection gives the individual and
their family more time to process the hard truth of the terminal
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illness, but typically provides a longer life span for that
individual during such a crucial time. While the individual is in
the early stage of memory loss, they are still mostly themselves
and can make decisions regarding their future.
Education for the individuals and their families is another
area that should be considered. In some cases, when individuals
who seem to be “too young” for an AD diagnosis, they may be
dismissed and not taken seriously regarding the various signs or
symptoms they are experiencing. It can appear as depression or
stress induced, thus negating to press the individual’s concern
(Ahmed, Baker, & Butler, 2016). Ultimately, it may even result
in false reassurance to the individual by examining only the
status of age (Ahmed, Baker, & Butler, 2016). If there was an
increase in knowledge about the disease and how early an
individual can display symptoms, it may help influence the
individual to take the necessary steps to get tested early, rather
than wait. In addition, continuing to stay educated and up to
date about the current AD research could help the practitioner
to stay alert and aware of young individuals who they might not
otherwise have expected to have AD (Black, 2019).
Consequences on Healthcare Service Deliveries
Early detection for AD may lead to a rise in the 16.1 million
Americans that are providing unpaid care for these individuals
(Alzheimer’s Associatio, 2019). Although this may be true, the
bigger fact to consider is that early detection and diagnosis of
this disease saves both families and the U.S. government large
sums of money. Even just a portion of the collective money
saved could then be turned right back toward the unpaid
caregivers for this population, reimbursement for neurological
exams for early testing of AD, and research to find a cure or
prevention of this terminal illness.
Early detection of AD provides many benefits. The major
benefit is through use of exams and testing, which allows the
practitioner to be certain that the individual does in fact suffer
from this illness, and that the symptoms are not caused by
something else. In addition, it provides time for the individuals
to manage the care of their mild cognitive impairments before
they progress to a later stage and develop dementia. Another
benefit is that by detecting the disease early, the family can
prepare and decide how they will spend their money for the
journey toward the individual needing constant care and
medical attention. When viewing the situation through an
emotional lens, early detection also provides time for the
individual and family to understand the lifestyle modifications
and fluctuations, changes in the individual’s perception of their
quality of life, as well as pushing past the associated stigmas
and understanding the reality.
Conclusion
More Americans are suffering from late diagnoses of
Alzheimer’s disease in the U.S. each year; therefore, there is a
need for more access toward early detection of this disease to
ensure optimal quality of life and treatments for individuals to
financially afford care. AD can develop in the beginning of
middle adulthood, but with various reasonings for a lack of
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access to care, they may go untreated for many years. The
individuals may not be able to afford the cost of testing, may
avoid testing due to labels and stigma, or may not even
recognize the extent of their cognitive impairment. More
governmental assistance needs to be placed into action for
research and advancements in AD, because without it, AD may
continue to climb the ladder of leading causes of death and
affect more and more individuals without ever having a cure.
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